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2STEPP (Substance Abuse Treatment, Education and 
Prevention Program)
vMultifaceted substance abuse treatment clinic with prenatal care
v Prescription of Suboxone 
v Group and individual counseling
• Focus on preparation for baby, empowerment and self-esteem
• Social workers are available for individual
• Referrals to more intensive psychiatric care when necessary 
v High risk obstetric care and infectious disease
• Ultrasounds 
• Hepatitis C and HIV
v Newborn planning
• In coordination with Nationwide Children’s OSU NICU
3Medication Assisted Treatment (MAT)
v Drugs occupy opioid receptors to relieve withdrawal and some cravings
vMethadone, Suboxone, Subutex
• STEPP physicians prescribe Suboxone (buprenorphine/naloxone)
v Reduces neonates risk and severity of Neonatal Abstinence Syndrome 
(NAS)
• Also reduces risk of exposure to contaminants in illicit drugs and 
overdose
4Purpose
v Literature reports of pregnant women with OUD and a comorbid psychiatric 
disorder shows a wide prevalence range of 21-72%
• These may contribute to poorer treatment adherence 
v The purpose of this research is to describe psychiatric diagnoses and 
explore relationships among comorbidities and program adherence. 
5Method
v Retrospective medical chart review of 411 patients
• Non-Hispanic, white (90.1%)
• Single (77.5%)
• Medicaid insurance (91.3%)
• Mean age of 27.72 (SD = 10.622)
• Mean gestational age at birth 38.39 weeks (SD = 1.934)
v 67.14% being treated with buprenorphine/naloxone, and 28.29% being 
treated with methadone at the time of delivery.
6Results
v Half of the patients (52.50%) had at least one psychiatric diagnosis 
during pregnancy 
• 92.3 % of these patients had a historical diagnosis
• 23.4% had a history of a suicide attempt 
• 65.5% had a documented illicit substance use during pregnancy 
other than opiates 
Mood
Anxiety
Trauma
SMI (Bipolar 
or Psychosis)
Personality Other
Suicide 
attempt
Suicidal 
Ideation
7Results
v Analyses exploring relationships between substance use, program 
adherence, and psychiatric diagnoses found that women with comorbid 
psychiatric diagnoses were more likely to test positive for an illicit 
substance during pregnancy other than opiates. 
v Also more likely to not be in treatment at time of delivery, have 
psychosocial stressors during pregnancy, and have a history or physical 
and or sexual abuse
8Conclusions
v Higher rate of comorbid psychiatric diagnoses than expected based on 
literature 
v Unique layout of this clinic likely contributed to greater attention to 
psychiatric care 
v Data suggests that women with comorbid psychiatric diagnoses were 
less likely to stay in treatment and have more likely to polysubstance 
use when entering treatment
• This difference in polysubstance use dissipates by delivery
• Suggests that STEPP plays a role in eliminating additional drug 
use that is associated with psychiatric conditions
ü These results highlight the important of including psychiatric care in 
prenatal MAT
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